[8-K] MAIA Biotechnology, Inc. Reports Material Event

Rhea-AI Filing Summary

Maris-Tech Ltd. (Nasdaq: MTEKW) furnished a Form 6-K to report a press release dated 28 July 2025. The release announces that the company obtained a $144,000 order from an undisclosed defense-industry customer for the design and development of a ruggedized AI processing platform. The first three paragraphs of the press release and its forward-looking-statement disclaimer are automatically incorporated into Maris-Tech’s effective Form S-8 and Form F-3 registration statements.

• No balance-sheet, income-statement, backlog or margin data accompany the filing; the order value is the only quantitative disclosure.
• Customer identity, delivery timetable and profitability metrics are not provided.

The award evidences initial traction for Maris-Tech’s edge-AI technology in the defense vertical, but its modest size limits near-term financial impact.

Positive

• Defense customer order: validates Maris-Tech’s AI platform compliance with ruggedized military requirements.
• Regulatory incorporation: seamless integration into existing S-8 and F-3 shelves may streamline future capital raises.

Negative

• Small contract value: $144k is unlikely to move revenue or earnings materially.
• Lack of detail: no timetable, margin data or customer identity, limiting visibility into future scale.
• No updated guidance: management provides no commentary on how the order affects 2025 outlook.

Insights

Financial Analyst

TL;DR: Small defense order modestly validates technology but is financially immaterial; neutral to valuation.

The $144k contract adds incremental revenue and signals market acceptance of Maris-Tech’s ruggedized AI modules. However, the figure represents a fraction of annual sales for even a micro-cap issuer, and the filing lacks margin or follow-on potential details. Because no guidance changed and the customer is unnamed, I view the event as informational rather than transformational. Investors may view it as a pipeline proof-point, yet its immediate impact on cash flow and EPS will be negligible.

Defense Industry Specialist

TL;DR: Defense-sector interest is strategically positive; order size indicates preliminary engagement, not full program adoption.

Securing any defense-industry contract suggests Maris-Tech meets ruggedization and security standards, a crucial barrier to entry. If the trial succeeds, larger production orders could follow. Still, $144k likely covers prototype design, so revenue visibility beyond the initial phase is uncertain. Without program details or government end-user confirmation, strategic upside remains speculative. Therefore, the announcement is encouraging but not materially impactful at this stage.

false 0001878313 0001878313 2025-07-28 2025-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2025

MAIA Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41455		83-1495913
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

444 West Lake Street, Suite 1700
Chicago, IL		60606
(Address of principal executive offices)		(Zip Code)

(312) 416-8592

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		MAIA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 28, 2025, the Company issued a press release announcing the FDA fast-track designation for Ateganosine as a treatment for non-small cell lung cancer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Forward-looking Statements

The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates. Any forward-looking statement speaks only as of the date on which it was made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated July 28, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 28, 2025

	MAIA BIOTECHNOLOGY, INC.
	By:	/s/ Vlad Vitoc
	Name:	Vlad Vitoc
	Title:	Chief Executive Officer

3

FAQ

What did Maris-Tech (MTEKW) announce in its July 28 2025 Form 6-K?

The company reported a $144,000 defense-industry order to design and develop a ruggedized AI platform.

How large is the new contract secured by Maris-Tech?

The order is valued at $144,000, covering design and development work only.

Does the filing include updated financial results or guidance?

No. The 6-K contains no financial statements or revised outlook.

Why are parts of the press release incorporated by reference into Form S-8 and Form F-3?

Incorporation allows the disclosed information to become part of those registration statements without separate amendments.

Is the identity of the defense customer disclosed?

No, the customer remains undisclosed in the filing.

Could this order lead to larger follow-on contracts?

Potentially, but the filing provides no indication of future order size or probability.